178 related articles for article (PubMed ID: 32758364)
41. Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management.
Kalisz KR; Ramaiya NH; Laukamp KR; Gupta A
Radiographics; 2019; 39(7):1923-1937. PubMed ID: 31584861
[TBL] [Abstract][Full Text] [Related]
42. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
Cousin S; Italiano A
Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
[TBL] [Abstract][Full Text] [Related]
43. Immune-Related Adverse Events From Immune Checkpoint Inhibitors.
Marrone KA; Ying W; Naidoo J
Clin Pharmacol Ther; 2016 Sep; 100(3):242-51. PubMed ID: 27170616
[TBL] [Abstract][Full Text] [Related]
44. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting.
Corbaux P; Maillet D; Boespflug A; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Dalle S; Falandry C; Péron J
Eur J Cancer; 2019 Nov; 121():192-201. PubMed ID: 31590080
[TBL] [Abstract][Full Text] [Related]
45. Checkpoint Inhibition in Myeloma: Opportunities and Challenges.
Costa F; Das R; Kini Bailur J; Dhodapkar K; Dhodapkar MV
Front Immunol; 2018; 9():2204. PubMed ID: 30319648
[TBL] [Abstract][Full Text] [Related]
46. Immune Checkpoint Inhibitors in Organ Transplant Patients.
Kittai AS; Oldham H; Cetnar J; Taylor M
J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
[TBL] [Abstract][Full Text] [Related]
47. Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.
Tray N; Weber JS; Adams S
Cancer Immunol Res; 2018 Oct; 6(10):1122-1128. PubMed ID: 30279188
[TBL] [Abstract][Full Text] [Related]
48. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.
Azoury SC; Straughan DM; Shukla V
Curr Cancer Drug Targets; 2015; 15(6):452-62. PubMed ID: 26282545
[TBL] [Abstract][Full Text] [Related]
49. Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis.
Su Q; Zhang XC; Zhang CG; Hou YL; Yao YX; Cao BW
J Immunol Res; 2018; 2018():1027323. PubMed ID: 29971244
[TBL] [Abstract][Full Text] [Related]
50. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
51. Vasculitis associated with immune checkpoint inhibitors-a systematic review.
Daxini A; Cronin K; Sreih AG
Clin Rheumatol; 2018 Sep; 37(9):2579-2584. PubMed ID: 29923081
[TBL] [Abstract][Full Text] [Related]
52. Emerging Immunotargets and Immunotherapies in Prostate Cancer.
Montironi R; Santoni M; Sotte V; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Berardi R; Scarpelli M
Curr Drug Targets; 2016; 17(7):777-82. PubMed ID: 26898309
[TBL] [Abstract][Full Text] [Related]
53. Checkpoint inhibitors: outstanding efficacy but at what cost?
Klastersky JA
Curr Opin Oncol; 2016 Jul; 28(4):253. PubMed ID: 27163724
[No Abstract] [Full Text] [Related]
54. Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies.
Allard B; Allard D; Stagg J
Methods Mol Biol; 2016; 1458():159-77. PubMed ID: 27581021
[TBL] [Abstract][Full Text] [Related]
55. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
56. Preface: More than two decades of modern tumor immunology.
Galluzzi L; Rudqvist NP
Methods Enzymol; 2019; 629():xxi-xl. PubMed ID: 31727259
[No Abstract] [Full Text] [Related]
57. Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities.
Renna CE; Dow EN; Bergsbaken JJ; Leal TA
J Oncol Pharm Pract; 2019 Jun; 25(4):954-960. PubMed ID: 30975067
[TBL] [Abstract][Full Text] [Related]
58. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
59. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice.
Massari F; Nunno VD; Mollica V; Montironi R; Cheng L; Cimadamore A; Blanca A; Lopez-Beltran A
Immunotherapy; 2019 Dec; 11(17):1507-1521. PubMed ID: 31663411
[TBL] [Abstract][Full Text] [Related]
60. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
Hermel DJ; Ott PA
Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
